In the final episode, "Long-Term VMS Management and Key Takeaways for Clinical Practice," the panelists explore the critical importance of viewing menopause management as a long-term, patient-centered endeavor rather than a time-limited intervention.
This episode, titled "Emerging Evidence on NK Receptor Antagonism and Bone Health in VMS," features panelists examining the exploratory endpoints from the OASIS 3 trial and what they may signal about elinzanetant's potential effects beyond VMS relief.
In "Evaluating Newer Non-Hormonal Therapies for VMS," our panel explores the similarities and distinctions between fezolinetant and elinzanetant as NK receptor antagonists, with a focus on how these differences inform clinical decision-making for a patient with inadequate response to MHT.
Menopause brain fog hits careers hard; learn sleep-focused, nonhormonal and hormone options for vasomotor symptoms—guided by patient comfort.
Learn how experts reassess persistent hot flashes after hormone therapy, uncover hidden factors, and combine nonhormonal options for relief.
Tailored follow-ups track lipids, blood pressure, and screenings while coordinating cardiology and endocrinology to manage vasomotor symptoms and reduce cardiovascular risk.
Learn how clinicians debunk hormone therapy myths, set expectations for symptom relief, and tailor menopause care with risk checks and referrals.
Hot flashes and night sweats derail daily life—see how primary care addresses WHI myths and considers safe menopause hormone therapy.
Learn how clinicians monitor liver safety for hot-flash therapies, compare lab schedules, and build multidisciplinary care for cancer patients.
Compare liver-monitoring needs for vasomotor drugs like fezolinetant, and see why multidisciplinary menopause care matters in oncology.
Elinzanetant eases hot flashes fast by targeting KNDy neurons, boosting sleep and helping cancer patients stay on endocrine therapy.
Learn how to manage hot flashes and insomnia in breast cancer survivors with NCCN-backed nonhormonal options like elinzanetant.
A breast cancer survivor on anastrozole struggles with relentless hot flashes and insomnia—explore evidence-based, nonhormonal relief options.
Clinicians break down hot flash impact and compare lifestyle, hormone, SSRI/SNRI, and new NK3 therapies using real patient cases.
June 9th 2026
